文献速递神经肿瘤

免疫检查点调节因子B7-H3(CD276)在人脑膜瘤中的表达及临床意义

Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
PubMed 文献 · World Neurosurg · 2019-10-16

该研究在单中心242例脑膜瘤患者中探索B7-H3等免疫检查点蛋白的表达。B7-H3在所有标本中均有表达,且显著高于其他检查点蛋白,其表达与患者性别、肿瘤病理亚型及术后放疗相关,但与无进展生存期和总生存期无关。

要点

  • B7-H3在脑膜瘤中普遍表达且高于其他免疫检查点蛋白。
  • B7-H3高表达与性别、病理亚型及术后放疗相关。
  • B7-H3表达与无进展生存期和总生存期无显著差异。

核心结论

  • B7-H3在脑膜瘤中表达可变,可能作为未来免疫治疗靶点。

研究设计与样本

  • 单中心回顾性队列,总样本242例;先以8例测试队列用免疫组化探索免疫检查点蛋白表达,再以234例扩大队列用组织芯片免疫组化评估B7-H3。

主要发现

  • B7-H3表达显著高于所研究的其他免疫检查点蛋白。
  • B7-H3在所有脑膜瘤标本中均有不同程度表达,主要位于肿瘤细胞膜和细胞质。
  • B7-H3表达与患者性别(P=0.0297)、肿瘤病理亚型(P=0.0262)及术后放疗(P=0.0028)显著相关。
  • B7-H3高表达组与低表达组在年龄、肿瘤位置、分级及切除程度上无显著差异。
  • B7-H3高表达组与低表达组在无进展生存期和总生存期上无显著差异。

关键数值与推荐

  • 根据免疫组化组织评分(histoscore)中位数111.06(范围7.313-212.008)将肿瘤分为B7-H3高表达组和低表达组。

临床怎么用

  • B7-H3在脑膜瘤中广泛表达且与部分临床特征相关,但当前数据未显示其与生存相关,尚不能用于预后分层。

局限性

  • 单中心回顾性设计,样本量有限,结果需外部验证。
  • 未报告多因素分析,无法排除混杂因素影响。
  • B7-H3与生存无显著关联,其临床转化价值尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The high expression across multiple tumor types and restricted expression in normal tissues make B7-H3 an attractive target for immunotherapy. So far, little is known about the clinical significance of B7-H3 expression in meningiomas. We conducted this study to address this issue in a cohort of 242 patients from a single institution. METHODS: Expression profiles of immune checkpoint proteins (programmed death-ligand 1, B7-H3, lymphocyte activation gene-3, programmed death 1, and V-domain Ig suppressor of T cell activation) were explored by immunohistochemistry in a meningioma test cohort (n = 8). Role of B7-H3 expression was further assessed in an expanded patient cohort (n = 234) using immunohistochemical tissue microarray analysis. RESULTS: B7-H3 expression was significantly greater than all immune checkpoint proteins studied in the tested cohort. B7-H3 was detected with different degrees in all meningioma specimens, predominantly on tumor cell membranes and in cytoplasm. Tumors were classified as B7-H3 high or low group depending on immunohistochemistry histoscore (median histoscore 111.06; range, 7.313-212.008). B7-H3 expression was statistically correlated with patient sex (P = 0.0297), tumor histopathologic subtypes (P = 0.0262), and radiotherapy after surgery (P = 0.0028). However, no significant differences were observed in patient age, tumor location, and grade and extent of resection between groups. Similarly, there was no significant difference in progression-free survival and overall survival between B7-H3 high and low group. CONCLUSIONS: Our study indicates variable expression and clinical role of B7-H3 in meningiomas, suggesting its potential as an immunotherapeutic target in the future.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Deng J, Ma M, Wang D, et al. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma. World Neurosurg. 2019. PMID: 31629137. doi:10.1016/j.wneu.2019.10.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。